<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Berry Genomics Co. Ltd. Class A — News on 6ix</title>
    <link>https://6ix.com/company/berry-genomics-co-ltd</link>
    <description>Latest news and press releases for Berry Genomics Co. Ltd. Class A on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 05 Nov 2025 21:02:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/berry-genomics-co-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683652de78dffbe2df156444.webp</url>
      <title>Berry Genomics Co. Ltd. Class A</title>
      <link>https://6ix.com/company/berry-genomics-co-ltd</link>
    </image>
    <item>
      <title>PacBio Announces Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/berry-genomics-co-ltd/news/pacbio-announces-third-quarter-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/berry-genomics-co-ltd/news/pacbio-announces-third-quarter-2025-financial-results</guid>
      <pubDate>Wed, 05 Nov 2025 21:02:00 GMT</pubDate>
      <description>MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4 million$40.0 millionInstrument revenue$11.3 million$16.8 millionConsumable revenue$21.3 million$18.5 millionService and other revenue$5.8 million$4.7 millionRevio™ systems1322Vega™ systems32—Annualized Revio pull-through per system~$236,000~$255,000Cash, cash equivalents, and investments$298.7 mil</description>
    </item>
    <item>
      <title>PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China</title>
      <link>https://6ix.com/company/berry-genomics-co-ltd/news/pacbio-supports-berry-genomics-in-achieving-first-regulatory-approval-for-clinical-long-read-sequencing-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/berry-genomics-co-ltd/news/pacbio-supports-berry-genomics-in-achieving-first-regulatory-approval-for-clinical-long-read-sequencing-in-china</guid>
      <pubDate>Tue, 04 Nov 2025 14:05:00 GMT</pubDate>
      <description>NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemiaMENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world&apos;s most advanced sequencing technologies, today announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medi</description>
    </item>
  </channel>
</rss>